AzTrials
AzTrials

Diabetes Mellitus, Type IIWalk@WorkNCT04092738

´Sit Less, Move More' at Work: mHealth Intervention on Office Employees With Diabetes Type 2.

A study testing Walk@WorkApp-Diab in people with Diabetes Mellitus, Type II, run by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The objective of the study is measuring the impact of a ´sit less, move more' mHealth intervention at work on the glycaemic control and anthropometric profile of office employees with diabetes type 2 (DT2) at short, mid and long term. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Diabetes Mellitus, Type II
What is being tested?
Walk@WorkApp-Diab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
368 participants
Where
1 siteSpain
Study dates
4 Mar 2019to Sep 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • DM2 diagnosed office employees according to international criteria.
  • Doing sedentary tasks during at least a 55% of their daily work schedule (according to the Occupational Sedentary and Physical Activity Questionnaire: OSPAQ >55%).
  • Having a cellphone .
  • Having a minimum work contract of 18.5 hours per week.
  • Being able to get up from the chair or to walk by themselves (without any help).

Who cannot join

  • Not having a cellphone.
  • Having some pathology/disability/injury which changes their ability and capacity to walk or getting up from the chair.
  • Doing less than a 55% of the daily tasks in a sitting position according to the OSPAQ questionnaire.

Trial locations and contacts

1 site in 1 country.

Anna Puig-Ribera contact

+34 619352497

annam.puig@uvic.cat

Francesc Alos Colomer contact

+34 618429646

cesc.alos@gmail.com

Spain1 site, 1 recruiting
  • IDIAP Jordi Gol

    Barcelona, 08007

    Francesc Alos Colomer, +34 618429645, cesc.alos@gmail.com

    Recruiting

Other trials in Spain

About this study

Official title: ´Sit Less, Move More' at Work: Impact of a mHealth Intervention on the Glycaemic Control and Anthropometric Profile of Office Employees With Diabetes Type 2. A Randomized Controlled Trial.

The objective of the study is measuring the impact of a ´sit less, move more' mHealth intervention at work on the glycaemic control and anthropometric profile of office employees with diabetes type 2 (DT2) at short, mid and long term.

Read the detailed description

A double-blind randomized controlled trial. Seven Primary Care Centers from Spain (n=5 Catalonia, n=2 Madrid), 2 hospitals (n=1 Catalonia, n=1 Madrid) and 2 companies (occupational health services; n=1 public, n=1 private) will participate in the study. In each center, physicians, nurses, endocrinologists and occupational physicians will recruit patients with DT2 who spend at least 55% of their working hours doing desk-based tasks (OSPAQ) and have a cellphone. Following the CONSORT Statement (2010), volunteers will be randomized into a control (CG) or intervention group (IG) by the research team using a computer program to generate the random sequence. 184 individuals are needed in each group. Main variables: fasting glucose levels, HbA1c, weight, height, BMI, waist circumference. Occupational sitting time and sitting time breaks will be measured using ActivPAL devices. Other variables: physical activity (IPAQ short), quality of life (EuroQool), presenteeism (WLQ), triglycerides, total cholesterol (LDL and HDL), blood pressure and sociodemographic variables.

Intervention: A mHealth program (13 wks) will progressively replace occupational sitting time with light physical activities. Participants from the CG will receive usual care. Multivariate analysis will assess changes over time (post intervention and at 6 months follow up) in the dependent variables; looking at differences between groups. Intention to treat will be applied.

Being tested
Walk@WorkApp-Diab
Keywords
mHealth, Physical Activity, Glucose, Blood, Glycated Hemoglobin A1c, Health-Related Quality Of Life, Quality of Life, Triglycerides, HDL Cholesterol, LDL Cholesterol, Blood Pressure, Arterial, Presenteeism, Sitting time, Sedentary Behaviour, Workplace
Medical subject headings
Diabetes Mellitus, Type 2, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Walk@WorkApp-DiabBehavioural

    Also called mHealth intervention

    The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones

Study groups in NCT04092738
Study groupRoleWhat they receive
Intervention GroupExperimentalIn the intervention group, subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2. In addition, participants will be provided with an external movement sensor that will be linked to the Walk@WalkApp-Diab for Android and iOS. This App will monitor the time participants spend sitting, walking and standing during working hours. It will also provide participants with strategies to "sit less and move more" at work throughout 13 weeks. This mHealth intervention aims to change occupational sitting by replacing desk-based activities by active tasks.
Receives: Behavioral: Walk@WorkApp-Diab
Control GroupNo interventionSubjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Fasting glucose levels

    Blood tests

    Measured: Two measurement points: (a) Before the intervention starts, (b) at 6 months after intervention has finished

  2. Change in concentration of HbA1c

    Blood tests

    Measured: Two measurement points: (a) before the intervention starts, (b) at 6 months after intervention has finished.

  3. Change in weight

    Body weight in kilograms (electronic scale-Seca 899/217)

    Measured: Three measurement points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after intervention has finished.

  4. Change in height

    Body height in metres (electronic scale-Seca 899/217)

    Measured: Three measurement points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after intervention has finished.

  5. Change in Body Mass Index

    Weight and height will be combined to report Body Mass Index (kg/m2)

    Measured: Three measurement points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after intervention has finished.

  6. Change in Waist circumference

    Waist circumference in centimetres using a flexible steel tape (Seca 203)

    Measured: Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished

Secondary outcomes (4)
  1. Change in objective Occupational sedentary behaviour

    Total sitting time (minutes/day), sedendary bouts (daily time spent sitting on less than 20 minutes periods, between 20-60 minutes periods, more than 60 minutes period (ActivPal device)

    Measured: Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.

  2. Change in subjective domain-specific sedentary behaviour

    Workforce Sitting Questionnaire (daily time spent sitting watching TV, working, at home, as transport and for leisure during working days and nonworking days (minutes/day)

    Measured: Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.

  3. Change in objective occupational physical activity

    Minutes/day spent doing light and moderate-to-vigorous physical activity (ActivPal device)

    Measured: Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.

  4. Change in subjective occupational physical activity

    Minutes/day walking, doing moderate and vigorous physical activity (International Physical Activity Questionnaire, IPAQ)

    Measured: Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2019
  2. Study start4 Mar 2019
  3. Primary completionJan 2020 (estimated)
  4. Study completionSep 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized controlled trial.
Masking
Single blind
Who is masked
Participant
Enrolment
368 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04092738
Sponsor's protocol ID
PI17/01788
Acronym
Walk@Work
Status last verified
Sep 2019
First submitted
16 Jul 2018
Last updated
17 Sep 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Alos F, Colomer MA, Bort-Roig J, Martin-Cantera C, Minaya A, Saigi I, Sitjar-Suner M, Puig-Ribera A. Impact of a primary care-based mobile health intervention to 'sit less and move more' on HbA1c, blood pressure, and other clinical outcomes in office employees with type 2 diabetes: A randomized controlled trial. Prim Care Diabetes. 2025 Oct;19(5):434-445. doi: 10.1016/j.pcd.2025.05.010. Epub 2025 Jun 9.

    PubMed 40494751
  • Alos F, Colomer MA, Martin-Cantera C, Solis-Munoz M, Bort-Roig J, Saigi I, Chirveches-Perez E, Sola-Gonfaus M, Molina-Aragones JM, Puig-Ribera A. Effectiveness of a healthcare-based mobile intervention on sedentary patterns, physical activity, mental well-being and clinical and productivity outcomes in office employees with type 2 diabetes: study protocol for a randomized controlled trial. BMC Public Health. 2022 Jun 29;22(1):1269. doi: 10.1186/s12889-022-13676-x.

    PubMed 35768818
  • Bort-Roig J, Chirveches-Perez E, Garcia-Cuyas F, Dowd KP, Puig-Ribera A. Monitoring Occupational Sitting, Standing, and Stepping in Office Employees With the W@W-App and the MetaWearC Sensor: Validation Study. JMIR Mhealth Uhealth. 2020 Aug 4;8(8):e15338. doi: 10.2196/15338.

    PubMed 32459625

Questions about this trial

What is this clinical trial studying?

A study testing Walk@WorkApp-Diab in people with Diabetes Mellitus, Type II, run by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anna Puig-Ribera (+34 619352497, annam.puig@uvic.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Fasting glucose levels (time frame: Two measurement points: (a) Before the intervention starts, (b) at 6 months after intervention has finished). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04092738, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2019; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in